Joshua Brody, MD

Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.

Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Joshua Brody, MD, discusses Fas and its impact on bystander killing in patients with non-Hodgkin lymphoma.

Joshua Brody, MD, discusses addressing required resistance to immunotherapy in non-Hodgkin lymphoma.

Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.